Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00921804 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 296
- Enrollment target
NCT00921804 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 296 participants.
The verdict
NCT00921804, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 296 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether treatment with daily oral dose of AZD8529 40 mg administered over 28 days is safe, well tolerated and improves main symptoms of schizophrenia in adult schizophrenia patients.
Interventions
- DRUG Risperidone
- DRUG Placebo to match AZD8529
- DRUG AZD 8529
- DRUG Placebo to match risperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 296 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00921804
The ClinicalTrials.gov registry entry for NCT00921804 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 296 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Risperidone is the first listed.
NCT00921804 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00921804 about?
NCT00921804 is a clinical study titled "Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients". The purpose of this study is to determine whether treatment with daily oral dose of AZD8529 40 mg administered over 28 days is safe, well tolerated and improves main symptoms of schizophrenia in adult schizophrenia patients.
What is the current status of trial NCT00921804?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 296 participants. The study started on 2009-06. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00921804?
The interventions under investigation include: Risperidone (DRUG), Placebo to match AZD8529 (DRUG), AZD 8529 (DRUG), Placebo to match risperidone (DRUG).
Who is sponsoring clinical trial NCT00921804?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.